Intravitreal Bevacizumab with or Without Triamcinolone for Refractory Diabetic Macular OedemaReportar como inadecuado




Intravitreal Bevacizumab with or Without Triamcinolone for Refractory Diabetic Macular Oedema - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Collegium antropologicum, Vol.34 supplement 2 No.2 April 2010. -

We evaluate the effect of intravitreal injections of Bevacizumab IVB alone or combined with triamcinolone IVT in the first injection for treatment of refractory diabetic macular oedema DME. Sixty eyes of sixty patients with refractory DME were included. Half of the receive injections of IVB 1.25 mg-0.05 mL or combined IVB and IVT 1.25 mg-0.05 mL and 2 mg-0.05 mL respectively. The primary outcome measure was change in central macular thickness CMT. Secondary outcome measures were change in best-corrected logMAR visual acuity BCVA and incidence of potential adverse events. Central macular thickness was reduced significantly in both the IVB and IVB-IVT groups. At week 24, CMT change compared to the baseline was –95.7 mm 95% CI, –172.2 to –19.26 in the IVB group and –92.1 mm 95% CI, –154.4 to –29.7 in the IVB-IVT group. There was not a significant difference between the IVB and the IVB-IVT groups p= 0.022. Improvement of BCVA was initiated at weeks 6 and 12 in the IVB-IVT and IVB groups respectively. In terms of BCVA change compared to the baseline at 24 weeks, the differences between the IVB and the IVB-IVT groups p=0.006 were significant. Anterior Chamber reaction was noticed in six 20% and six 20% eyes respectively in the IVB and IVB-IVT groups the day after injection, and it resolved with no sequel. Elevation of IOP occurred in two eyes 6% in the IVB- IVT group. Intravitreal injections of Bevacizumab had a beneficial effect on refractory DME in terms of CMT reduction and BCVA improvement. Addition of triamcinolone in the injection seemed to induce earlier visual improvement; however, it did not show any significant additive effect later during follow-up.

bevacizumab; diabetic macular oedema



Autor: Svatopluk Synek - ; Department of Ophthalmology and Optometry, Saint Anne Hospital, Medical Faculty Masaryk University, Brno, Cze

Fuente: http://hrcak.srce.hr/



DESCARGAR PDF




Documentos relacionados